Skip to main content
. 2011 May 2;108(20):8194–8199. doi: 10.1073/pnas.1018565108

Fig. 7.

Fig. 7.

Payload targeting in vivo. (A) IGF1R-Dig bispecifics charged with Dig-Cy5 were applied to H322M xenografts. IGF1R-Dig carries Dig-Cy5 to the xenograft, Dig-Cy5 without antibody appears in liver (circles) and becomes eliminated (Fig. S7). (B) Her2-Dig bispecifics specifically targets Dig-Dox to Calu3 xenografts. (C) Preapplication of bispecifics followed by Dig-Cy5 leads to specific capture of Dig-Cy5 at the tumor.